Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ABBV - AbbVie Inc.
Market Cap 263.55B P/E 35.15 EPS this Y -2.50% Ern Qtrly Grth -32.30%
Income 5.3B Forward P/E 13.52 EPS next Y 11.20% 50D Avg Chg 8.00%
Sales 55B PEG 2.69 EPS past 5Y 5.57% 200D Avg Chg -1.00%
Dividend 4.00% Price/Book 19.85 EPS next 5Y 6.26% 52W High Chg -11.00%
Recommedations 2.20 Quick Ratio - Shares Outstanding 1.77B 52W Low Chg 14.00%
Insider Own 0.10% ROA - Shares Float 1.76B Beta 0.62
Inst Own 72.70% ROE - Shares Shorted/Prior 16.38M/15.25M Price 149.38
Gross Margin 69.52% Profit Margin 9.71% Avg. Volume 5,937,400 Target Price 187.64
Oper. Margin 35.13% Earnings Date Oct 25 Volume 5,753,546 Change 0.57%
Healthcare | Drug Manufacturers - General | United States
About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. News
07/26/24 AbbVie's Immunology Products Continue to Deliver, Morgan Stanley Says
07/26/24 Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
07/26/24 Two biotechs cut staff; AbbVie weathers biosimilar threat
07/26/24 AbbVie’s Q2 2024 net earnings drop to $1.37bn
07/26/24 Company News for Jul 26, 2024
07/26/24 Q2 2024 AbbVie Inc Earnings Call
07/26/24 AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
07/25/24 Why AbbVie Stock Was Cruising Higher on Thursday
07/25/24 AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing
07/25/24 AbbVie (ABBV) Q2 2024 Earnings Call Transcript
07/25/24 AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio
07/25/24 AbbVie Stock Rises on Strong Sales of Immunology Drugs Other Than Humira
07/25/24 AbbVie stock gets lift after beating Q2 earnings estimates
07/25/24 Top Midday Stories: US Advance Q2 GDP Rises; Initial Jobless Claims Drop; Ford Earnings Fall; TotalEnergies' Lower Results; AbbVie Raises Guidance; IBM, ServiceNow Report Higher Results
07/25/24 New Drug Sales Lift AbbVie Stock
07/25/24 AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
07/25/24 AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
07/25/24 AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
07/25/24 Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
07/25/24 AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
ABBV Chatroom

User Image FIREGirl420 Posted - 4 hours ago

$PFE $GILD $BMY $ABBV What a week

User Image Pitbowl Posted - 4 hours ago

$ABT $MRMD $ABBV $AMGN $BAX https://www.bettyseddies.com/ https://marimedinc.com/brands

User Image Article_AI Posted - 9 hours ago

$ABBV AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. https://www.stck.pro/news/ABBV/86099486/

User Image Article_AI Posted - 10 hours ago

$ABBV Morgan Stanley Sticks to Their Buy Rating for AbbVie (ABBV) Morgan Stanley analyst Terence Flynn maintained a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $211.00. The compan... https://www.stck.pro/news/ABBV/86082268/

User Image TaylorTwits Posted - 11 hours ago

$ABBV crash time!!!!

User Image MontanaT Posted - 11 hours ago

$ABBV 200+

User Image Article_AI Posted - 11 hours ago

$ABBV Truist Financial Sticks to Their Buy Rating for AbbVie (ABBV) Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $210.00. T... https://www.stck.pro/news/ABBV/86079760/

User Image SonGoku Posted - 11 hours ago

52 week highs in $KO $LMT $MMM $ABBV

User Image RunUpABag Posted - 12 hours ago

$NXGL This small company has already landed supply deals with $CTAS and $ABBV , ONLY a 5 million FLOAT here 💎 Robust revenue guidance from the CEO with profitability around the corner… Pain data on their patches beats ANYTHING IN THE MARKET! 🌎

User Image PanicSeller8 Posted - 12 hours ago

$ABBV Trading only at 15X next year's earnings. 200+ on horizon.

User Image Chuckthebear Posted - 12 hours ago

$BMY reminds me of $ABBV 5 years ago. Same situation

User Image Article_AI Posted - 12 hours ago

$ABBV Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV) Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of $200.00. The c... https://www.stck.pro/news/ABBV/86079696/

User Image Kain_C64 Posted - 13 hours ago

$BMY $ABBV $100 by 2030 or sooner. $BMY is still a buy. This is ABBVIE 2.0. It will recover and surge!

User Image Gramma Posted - 13 hours ago

$ABBV Glad that andrew left of citron got arrested for securities fraud,They had a list of stocks he screwed around with and the years,He looks like an alcoholic!

User Image Bigjim00 Posted - 13 hours ago

$ABBV 200 here we come

User Image Vertical_Capital Posted - 13 hours ago

$NXGL First one here years ago...4 Mil Low Float! Ready to RUN! I still think we hit $8 to $15 from $3 here in NXGL! Huge Supply Agreement with $ABBV Abbvie will rollout 900 machines using NXGL pads soon... 5k-20k pads per machine per qtr...do the math $3.5/pad $AMD $NVDA Still running AI buying AI $GOOG too

User Image Article_AI Posted - 13 hours ago

$ABBV Buy Rating Affirmed for AbbVie: Strong Commercial Execution and Strategic Growth Post-Humira Analyst Evan Seigerman from BMO Capital assigned a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at $214.00. Evan Seig... https://www.stck.pro/news/ABBV/86079218/

User Image Stocksrunner Posted - 14 hours ago

$ABBV - AbbVie's Skyrizi gets EC approval for ulcerative colitis treatment. Expanding market reach in Europe. Keep an eye on pharma sector moves.

User Image Article_AI Posted - 14 hours ago

$ABBV Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal from Wells F... https://www.stck.pro/news/ABBV/86070023/

User Image Article_AI Posted - 15 hours ago

$ABBV Barclays Reaffirms Their Buy Rating on AbbVie (ABBV) Barclays analyst Carter Gould maintained a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $200.00. The company’s sha... https://www.stck.pro/news/ABBV/86069448/

User Image MontanaT Posted - 16 hours ago

$ABBV $200+

User Image Streetsweeper1 Posted - 16 hours ago

$ABBV $CGTX. Presenting at AAIIC next week. Phase 2 trial. Institutions own 1/3rd of company. Undervalued. $10 on strong news. Expecting PR on 7/28 when conference starts and their poster presentation will be accessible virtually! 7/29 will be a gap up! https://finance.yahoo.com/quote/CGTX/holders/

User Image PanicSeller8 Posted - 16 hours ago

$ABBV A stock to hold in any market climate.

User Image DonCorleone77 Posted - 21 hours ago

$ABBV AbbVie announces European Commission approval of Skyrizi AbbVie announced that the European Commission has approved Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

User Image DonCorleone77 Posted - 21 hours ago

$ABBV AbbVie price target raised to $200 from $187 at Barclays Barclays raised the firm's price target on AbbVie to $200 from $187 and keeps an Overweight rating on the shares. The company reported a strong quarter and raised the 2024 guidance, the analyst tells investors in a research note. The firm says AbbVie's 2025 growth messaging "incrementally de-risks" the over $12 in earnings per share for 2025.

User Image divalu Posted - 22 hours ago

@BryGuy91 $ABBV is my second largest position. 🍎 $AAPL is my first! Been in $ABBV since $ABT, which I no longer hold, spun shares off to me.

User Image Cousin_Vinny Posted - 1 day ago

$ABBV AbbVie Stock Jumps on #volume As Its New Golden Goose Looks To Overtake Humira #IBDpartner @InvestorsBusinessDaily $LLY $JNJ $BMY $ABBV Try Leaderboard > https://tinyurl.com/LeaderBd

User Image BryGuy91 Posted - 1 day ago

$ABBV Long this beast. Average is $113 woohoo!

User Image jbdever Posted - 1 day ago

$ABBV where’s the BEEF I mean DIV😜😜😜

User Image Article_AI Posted - 1 day ago

$ABBV ABBV Earnings: AbbVie Surpasses Q2 Expectations with Strong Immunology Sales AbbVie ($ABBV) reported strong results for the second quarter. The company announced adjusted diluted earnings of $2.65 per share, which is an 8.9%... https://www.stck.pro/news/ABBV/86031812/

Analyst Ratings
Cantor Fitzgerald Overweight Jul 26, 24
Truist Securities Buy Jul 26, 24
Wells Fargo Overweight Jul 26, 24
Barclays Overweight Jul 26, 24
BMO Capital Outperform Jul 19, 24
Morgan Stanley Overweight Jul 11, 24
Cantor Fitzgerald Overweight Jul 9, 24
Piper Sandler Overweight Jul 2, 24
Cantor Fitzgerald Overweight Jun 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT.. EVP, CHIEF BUS/STRAT OFFICER Dec 26 Sell 154.72 2,912 450,545 55,903 12/28/23
GONZALEZ RICHARD A CHAIRMAN OF THE BOAR.. CHAIRMAN OF THE BOARD AND CEO Jul 31 Sell 148.87 78,500 11,686,295 565,294 08/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Apr 17 Sell 161.84 7,499 1,213,638 35,330 04/19/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Sell 155 15,003 2,325,465 42,829 03/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Option 93.5 15,003 1,402,780 57,832 03/02/23
Siatis Perry C EVP, GC AND SECRETAR.. EVP, GC AND SECRETARY Feb 28 Sell 153.22 12,135 1,859,325 10,377 03/02/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Sell 151.02 28,541 4,310,262 37,921 02/21/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Option 62.09 14,179 880,374 66,462 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Option 51.42 25,000 1,285,500 258,208 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Sell 149.59 25,000 3,739,750 233,208 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Sell 151.02 15,321 2,313,777 62,679 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Option 105.92 15,321 1,622,800 78,000 02/21/23
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Option 104.59 79,801 8,346,387 231,904 05/25/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Sell 151.16 79,801 12,062,719 152,103 05/25/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Option 54.86 83,960 4,606,046 125,583 05/20/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Sell 155 83,960 13,013,800 41,623 05/20/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Option 78.23 200,000 15,646,000 252,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Sell 154.58 200,000 30,916,000 152,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Sell 151.2 300,000 45,360,000 152,103 05/10/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Option 57.21 300,000 17,163,000 252,103 05/10/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Option 58.88 27,690 1,630,387 88,631 03/25/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Sell 159.2 27,690 4,408,248 60,941 03/25/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Option 79.02 11,682 923,112 37,722 03/11/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Sell 150 18,628 2,794,200 19,094 03/11/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Mar 01 Sell 148.12 25,000 3,703,000 16,623 03/02/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Feb 25 Sell 148.43 15,000 2,226,450 41,623 03/01/22
Michael Robert A. Vice Chairman Vice Chairman Feb 25 Sell 148.32 43,105 6,393,334 37,877 03/01/22
Strom Carrie C SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth Feb 07 Sell 141.17 2,396 338,243 42,499 02/08/22
AUSTIN ROXANNE S Director Director Nov 02 Sell 116.42 71,844 8,364,078 49,284 11/04/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Sell 120 13,080 1,569,600 11,595 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Option 114.36 7,080 809,669 18,675 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Option 86.26 20,195 1,742,021 52,946 02/24/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Sell 105 20,195 2,120,475 32,751 02/24/21
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Option 51.42 51,990 2,673,326 51,990 12/01/20
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Sell 105 51,990 5,458,950 12/01/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Option 24.21 4,800 116,208 118,667 11/12/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Sell 93.61 4,800 449,328 113,867 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Option 56.87 194,154 11,041,538 512,796 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Sell 96.76 231,604 22,410,003 318,642 11/12/20